Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055767
Filing Date
2024-05-08
Accepted
2024-05-08 16:30:34
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nams-20240331.htm   iXBRL 10-Q 1624856
2 EX-31.1 nams-ex31_1.htm EX-31.1 15322
3 EX-31.2 nams-ex31_2.htm EX-31.2 15279
4 EX-32.1 nams-ex32_1.htm EX-32.1 8322
5 EX-32.2 nams-ex32_2.htm EX-32.2 8296
  Complete submission text file 0000950170-24-055767.txt   6072942

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nams-20240331.xsd EX-101.SCH 1154664
63 EXTRACTED XBRL INSTANCE DOCUMENT nams-20240331_htm.xml XML 661498
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41562 | Film No.: 24926691
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)